Metronomic chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative adjuvant therapy in colorectal cancer at high risk to recurrence.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of experimental & clinical cancer research : CR

• Publication date

  2007-12-01

• Fields of study

  Medicine

• Identifiers
  PMID 18365541
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal carcinoma.

  2007cited by this paper
• Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.

  2006cited by this paper
• Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy.

  2006cited by this paper
• The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer

  2006cited by this paper
• Capecitabine as adjuvant treatment for stage III colon cancer.

  2005cited by this paper
• Antibody against vascular endothelial growth factor (VEGF) inhibits angiogenic switch and liver metastasis in orthotopic xenograft model with site-dependent expression of VEGF.

  2005cited by this paper
• Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer

  2005cited by this paper
• Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity.

  2005cited by this paper
• Characteristic differences between patients who have undergone surgical treatment for lung metastasis or hepatic metastasis from colorectal cancer.

  2005cited by this paper
• Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

  2004cited by this paper
• The anti-angiogenic basis of metronomic chemotherapy

  2004cited by this paper
• Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.

  2003cited by this paper
• Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer.

  2001cited by this paper
• Redefining the target: chemotherapeutics as antiangiogenics.

  2001cited by this paper
• Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

  2000cited by this paper
• Feasibility of a novel weekday-on/weekend-off oral UFT schedule as postoperative adjuvant chemotherapy for colorectal cancer

  2000cited by this paper
• Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

  2000cited by this paper
• Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

  2000cited by this paper
• Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators.

  1999cited by this paper
• A multicenter, Phase II trial of weekly irinotecan (CPT‐11) in patients with previously treated colorectal carcinoma

  1999cited by this paper
• UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice.

  1999cited by this paper
• Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line.

  1998cited by this paper
• Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators.

  1995cited by this paper
• Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.

  1993cited by this paper

• Inhibition of Small-cell Lung Cancer Angiogenesis by Irinotecan Metronomic Chemotherapy and Irinotecan Plus Everolimus

  2025cites this paper
• Both XELIRI And TEGAFIRI Togetherwith Bevacizumab are Effective for Recurrent or Metastatic Colorectal Cancer: A Real-Life Experience

  2020cites this paper
• Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience

  2019cites this paper
• Metronomic chemotherapy and nanocarrier platforms.

  2017cites this paper
• Effect of antitumor drugs in low concentrationson the biological, immunophenotypic and cytogenetic characteristics of human colon cancer cells in vitro.

  2017cites this paper
• Current achievements and future perspectives of metronomic chemotherapy

  2017influential citation
• Quality of life in patients with metastatic breast cancer treated with metronomic chemotherapy.

  2016cites this paper
• TEGAFIRI is an effective alternative regimen for the management of recurrent or metastatic colorectal cancer

  2015cites this paper
• Adverse Side Effects Associated with the Use of Low-Dose Metronomic Chemotherapy

  2014cites this paper
• Metronomic chemotherapy

  2014cites this paper
• Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer.

  2013cites this paper
• [Development of siRNA delivery strategy by active control of tumor microenvironment].

  2013cites this paper
• Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients.

  2013cites this paper
• Metronomic chemotherapy for cancer treatment: a decade of clinical studies

  2013cites this paper
• Metronomic anti-cancer therapy - an ongoing treatment option for advanced cancer patients

  2012cites this paper
• Anti-angiogenic therapy for colorectal cancer: on the way to getting better!

  2012cites this paper
• Metronomic treatment with irinotecan (CPT-11) against malignant glioma xenografts inhibits angiogenesis and tumor growth

  2010cites this paper
• Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth

  2010cites this paper
• Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas

  2010cites this paper